Dr. Judith James receives 2019 Evelyn V. Hess Award

Dr. James, Oklahoma Medical Research Foundation (OMRF) Vice President of Clinical Affairs, will be honored for her 25 years of accomplishments and contributions to the lupus research field. Her work has resulted in over 280 publications, and she has led or participated in over 25 clinical trials and has been awarded over 50 federally funded grant projects.

A New Study Examines Cerebrovascular Events in Lupus Patients.

Stroke and transient ischemia are the most common cerebrovascular events in lupus patients, and a new study has found most of these occurrences can be attributed to lupus itself rather than other causes. Click here to find out more.

Dr. Dafna Galdman receives 2018 Distinguished Clinical Investigator Award

Congratulations to Dr. Dafna Gladman on receiving the 2018 American College of Rheumatology, Distinguished Clinical Investigator Award. Each year the American College of Rheumatology recognizes its members’ outstanding contributions to the field of rheumatology through an awards program.

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23 and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn’s disease. IL-12 and IL-23 have been implicated in systemic lupus erythematosus. We aimed to assess the efficacy and safety of ustekinumab for the treatment of systemic lupus erythematosus in patients with moderate-to-severe disease activity despite conventional treatment.

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR)

Systemic lupus erythematosus (SLE) is a complex multisystemic
autoimmune disease resulting, oftentimes, in irreversible
damage, diminished quality of life and reduced life expectancy.1–3
Genetic and environmental factors play important roles
in its pathogenesis.4–8 Disease manifestations and severity vary
according to the patients’ racial/ethnic background and socioeconomic
status (SES).

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

Systemic lupus erythematosus is a multisystem, chronic autoimmune disease characterised by the presence of antibodies directed at self-antigens, and broad immune dysregulation.

It is believed that abnormalities of both the innate and adaptive arms of the immune system, interconnected by a positive feedback loop, contribute to disease pathogenesis.